Genomind expands use of the Genecept™ Assay to children and adolescents with psychiatric disorders
CHALFONT, PA – October 22, 2013 – Genomind, a personalized medicine company, is pleased to announce their participation at the American Academy of Child & Adolescent Psychiatry (AACAP) 60th Annual Meeting, to be held October 22-27, 2013 in Orlando, Florida at the Walt Disney World Dolphin Hotel.
Between 7 and 12 million American youth suffer from mental, behavioral, or developmental disorders at any given time, and only 20% of children with mental disorders are identified and receive mental health services. Research shows, though, that early identification and intervention can minimize the long-term disability of mental illness.
Representing over 8,500 child and adolescent psychiatrists nationwide, the American Academy of Child and Adolescent Psychiatry is the leading authority on children’s mental health. AACAP members actively research, diagnose and treat psychiatric disorders affecting children, adolescents and their families. The Association is dedicated to treating and improving the quality of life for children, adolescents, and families affected by these disorders. Attracting over 4,000 attendees to the annual meeting, this is the largest meeting of its kind in the United States.
“Clinicians have used the Genecept Assay for thousands of their child and adolescent patients, and we are pleased for the opportunity to share new case studies at the Conference that highlight the power of making informed treatment decisions,” said Dr. Jay Lombard, Chief Scientific Officer and Medical Director, Genomind. “The AACAP is a leadership organization we are proud to support.”
Genomind will be exhibiting at Booth #422 where staff will share new data, case studies, and provide real world examples of how the Assay is being used in practice today.
About the Genecept Assay
The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/how-it-works/.
Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.
For more information, contact:
Marketing Manager, Genomind